Medicare will pay hospitals less for 340B drugs and off-campus scans in 2027
The final outpatient rule cuts what Medicare pays for drugs hospitals buy at a discount, and CMS estimates patients who get those drugs will save an average of $900 next year.

The Centers for Medicare & Medicaid Services (CMS) on Wednesday finalized its 2027 payment rule for hospital outpatient departments and ambulatory surgical centers. The rule sets Medicare's payment for drugs hospitals buy through the federal 340B discount program at the drug's average sales price minus 28%, and pays the lower physician office rate for many scans done at off-campus hospital clinics, according to the CMS fact sheet1.
CMS estimates the drug change will cut Original Medicare's drug spending by $4.35 billion and what beneficiaries pay for those drugs by $1.1 billion in 2027, a total drop of about $5.45 billion, according to the agency's press release2.
Why it matters
Medicare patients pay a share of what Medicare pays the hospital, so a lower payment rate means a smaller bill for the patient. CMS says a beneficiary who receives a qualifying drug in a hospital outpatient department will save an average of $900 in 2027.
The imaging change goes at a long-running gap in health care prices: the same scan often costs more when it is billed by a hospital-owned clinic than by an independent office. Under the rule, imaging without contrast at off-campus hospital outpatient departments, including X-rays, ultrasounds, CT and MRI scans and bone density scans, will be paid at the Physician Fee Schedule equivalent rate. Rural sole community hospitals are exempt.
The details
CMS estimates the imaging policy will save about $260 million in 2027 and more than $9 billion from 2027 to 2036, the agency said. The fact sheet puts the first-year cut in what beneficiaries pay out of pocket for these scans at about $70 million.
The 340B cut does not shrink total hospital outpatient payments. CMS made it budget neutral, so payments for other outpatient services rise by an equivalent amount, according to the fact sheet. The agency based the 28% figure on its own survey of what hospitals pay to acquire the drugs.
Overall outpatient and surgical center rates rise 2.3% in 2027 for facilities that meet quality reporting requirements. That is a 3.2% market basket increase minus a 0.9 percentage point productivity adjustment, the fact sheet says.
The rule also speeds up how quickly Medicare recovers money it paid hospitals to remedy earlier 340B payment cuts. The offset on non-drug payments rises from 0.5% to 2% a year, excluding hospitals that enrolled in Medicare after January 1, 2018, and continues until $7.8 billion has been recouped, which CMS expects in 2031. CMS will also remove 637 more services from the list of procedures Medicare pays for only when a patient is admitted as an inpatient, in the second year of a three-year phase-out.
"CMS is committed to spending taxpayer funds wisely and efficiently," CMS Administrator Dr. Mehmet Oz said in the release.
How it got here
The 340B program lets hospitals that serve many low-income patients buy outpatient drugs at steep discounts, while Medicare has historically paid them close to the full average sales price. Hospitals keep the difference between the discounted price and Medicare's payment. The remedy payments being recouped under this rule repaid hospitals for an earlier round of 340B payment cuts. The fact sheet does not mention any change to hospital price transparency rules.
What comes next
The payment rates take effect for services furnished in calendar year 2027. Watch whether hospitals that lose 340B revenue seek higher rates from commercial insurers in upcoming contract talks, and whether the incoming Congress takes up site-neutral payment more broadly.



